A phase I trial of AGX 1009 for Hepatitis B.
Phase of Trial: Phase I
Latest Information Update: 23 Jul 2013
At a glance
- Drugs AGX 1009 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- 23 Jul 2013 Agenix is poised to submit a new drug clinical trial application (CTA) for AGX-1009 with the China Food and Drug Administration (CFDA), according to a media release.
- 27 Mar 2013 An Agenix media release states that the company are still on track to submit a new drug clinical trial application in China.
- 05 Sep 2012 Planned initiation date changed from 1 Dec 2013 to 1 Jun 2014.